Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$15.75 - $53.69
Next Earnings Date
Apr 30 2025
Next Earnings Date
Apr 30 2025
Latest price
Market Cap | $1.10B |
EV | $1.14B |
Shares Outstanding | 66.56M |
Beta | 1.53 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $38.24 |
P/E 2025E | - |
P/Revenue 2025E | 1.10x |
Revenue | 10.20% |
EPS | - |
Operating Cash Flow | -39.90% |
Free Cash Flow | -62.80% |
Revenue | 8.60% |
EPS | 48.60% |
Operating Cash Flow | 74.60% |
Free Cash Flow | 66.40% |
Gross Margin 2025E | 53.87% |
Net Profit Margin 2025E | -7.73% |
ROE 2025E | -31.60% |
ROCE 2024 | -33.30% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Tandem Diabetes Care, Inc.
TNDM
Sector
Healthcare
Industry
Medical - Devices
CEO
Sheridan, John
Employees
2,650
Website
www.tandemdiabetes.comIPO Date
2013-11-14
Headquarters
12400 High Bluff Drive, San Diego, California, 92130, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved